Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms
Journal
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
Journal Volume
55
Journal Issue
3
Pages
359
Date Issued
2022-06
Author(s)
Sy, Cheng Len
Cheng, Chun-Wen
Huang, Ling-Ju
Wang, Ching-Hsun
Chang, Tu-Hsuan
Chang, Yi-Chin
Chang, Chia-Jung
Hii, Ing-Moi
Hsu, Yu-Lung
Hung, Pi-Lien
Kuo, Chen-Yen
Lin, Pei-Chin
Liu, Po-Yen
Lo, Ching-Lung
Lo, Shih-Hao
Ting, Pei-Ju
Tseng, Chien-Fang
Wang, Hsiao-Wei
Yang, Ching-Hsiang
Lee, Susan Shin-Jung
Chen, Yao-Shen
Liu, Yung-Ching
Wang, Fu-Der
Abstract
Antimicrobial drug resistance is one of the major threats to global health. It has made common infections increasingly difficult or impossible to treat, and leads to higher medical costs, prolonged hospital stays and increased mortality. Infection rates due to multidrug-resistant organisms (MDRO) are increasing globally. Active agents against MDRO are limited despite an increased in the availability of novel antibiotics in recent years. This guideline aims to assist clinicians in the management of infections due to MDRO. The 2019 Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group, comprising of infectious disease specialists from 14 medical centers in Taiwan, reviewed current evidences and drafted recommendations for the treatment of infections due to MDRO. A nationwide expert panel reviewed the recommendations during a consensus meeting in Aug 2020, and the guideline was endorsed by the Infectious Diseases Society of Taiwan (IDST). This guideline includes recommendations for selecting antimicrobial therapy for infections caused by carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales, and vancomycin-resistant Enterococcus. The guideline takes into consideration the local epidemiology, and includes antimicrobial agents that may not yet be available in Taiwan. It is intended to serve as a clinical guide and not to supersede the clinical judgment of physicians in the management of individual patients.
Subjects
CRAB; CRE; CRPA; Guideline; MDRO; VRE
SDGs
Publisher
ELSEVIER TAIWAN
Type
journal article